Bp Plc increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 13.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 163,000 shares of the biopharmaceutical company’s stock after buying an additional 19,000 shares during the period. Bp Plc’s holdings in Gilead Sciences were worth $11,069,000 as of its most recent filing with the SEC.

Several other institutional investors also recently added to or reduced their stakes in GILD. Abner Herrman & Brock LLC boosted its stake in Gilead Sciences by 0.5% in the first quarter. Abner Herrman & Brock LLC now owns 10,202 shares of the biopharmaceutical company’s stock worth $693,000 after buying an additional 50 shares during the period. Blue Fin Capital Inc. boosted its stake in Gilead Sciences by 0.8% in the first quarter. Blue Fin Capital Inc. now owns 7,213 shares of the biopharmaceutical company’s stock worth $489,000 after buying an additional 55 shares during the period. Searle & CO. boosted its stake in Gilead Sciences by 0.6% in the first quarter. Searle & CO. now owns 13,350 shares of the biopharmaceutical company’s stock worth $907,000 after buying an additional 80 shares during the period. Alpha Windward LLC boosted its stake in Gilead Sciences by 2.4% in the first quarter. Alpha Windward LLC now owns 3,921 shares of the biopharmaceutical company’s stock worth $266,000 after buying an additional 92 shares during the period. Finally, S&CO Inc. boosted its stake in Gilead Sciences by 1.5% in the first quarter. S&CO Inc. now owns 6,275 shares of the biopharmaceutical company’s stock worth $426,000 after buying an additional 95 shares during the period. Institutional investors and hedge funds own 74.02% of the company’s stock.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) traded down 0.331% during mid-day trading on Friday, reaching $73.775. The company’s stock had a trading volume of 1,103,916 shares. The company has a market capitalization of $96.34 billion, a price-to-earnings ratio of 8.013 and a beta of 1.21. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $82.07. The firm’s 50 day moving average price is $72.85 and its 200-day moving average price is $68.86.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company’s revenue for the quarter was down 8.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.08 earnings per share. On average, analysts predict that Gilead Sciences, Inc. will post $8.74 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be given a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.81%. The ex-dividend date is Thursday, September 14th. Gilead Sciences’s dividend payout ratio is 22.58%.

TRADEMARK VIOLATION WARNING: This piece was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/08/25/bp-plc-buys-19000-shares-of-gilead-sciences-inc-gild.html.

A number of research firms have recently commented on GILD. Berenberg Bank restated a “buy” rating and set a $86.00 target price (up from $79.00) on shares of Gilead Sciences in a research report on Sunday, August 20th. BidaskClub upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, August 19th. Zacks Investment Research upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $84.00 target price on the stock in a research report on Friday, July 28th. Cowen and Company restated an “outperform” rating and set a $90.00 target price on shares of Gilead Sciences in a research report on Thursday, July 27th. Finally, Deutsche Bank AG restated a “buy” rating and set a $81.00 target price (up from $79.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. Eleven analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $80.64.

In other news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the sale, the insider now directly owns 3,199,969 shares in the company, valued at $227,197,799. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the completion of the sale, the executive vice president now owns 106,113 shares of the company’s stock, valued at $8,051,854.44. The disclosure for this sale can be found here. Insiders sold 206,666 shares of company stock valued at $15,223,184 over the last three months. Insiders own 1.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.